A correspondence that discusses the development of a second generation bifunctional drug called DRhQ that can simultaneously bind to and inhibit both the TCR and CD74 through distinct regions of the construct.DRhQ is comprised of the HLA-DRa1 domain with an L50Q amino acid substitution (to enhance binding afinity for CD74) linked to an autoantigen peptide (myelin oligodendroglial cell glycoprotein, i.e. MOG-35-55 peptide)(Fig. 1)As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clin. trial(showing safety and tolerability) required MHC-matched recipients.Thus, the simpler DRhQ construct was designed, retaining just the conserved-in-human DRa1 domain (without the polymorphic HLA-DRβ1 domain) linked to the MOG-35-55 peptide extension, with the added benefit that it can be administered to all recipients without need for tissue type matching.This has enabled use of the DRα1-MOG-35-55 construct to reverse ongoing neuroinflammation and disease signs in animal models of multiple sclerosis, stroke, methamphetamine disorders and traumatic brain injury.These and other studies ([9-11]& unpublished data) revealed down-regulation of multiple proinflammatory components driven by both innate and adaptive immune responses that also contribute to the SARS-CoV-2 cytokine storm, including complement receptor C5aR1, platelet activation, IL-1β, IL-2, IL-6,TNF-αa, CCR2(receptor for CCL2) and CXCR2.Of further importance, a partial HLA-DP RTL construct could inhibit activated pleural T cell infiltrates from patients with beryllium-induced lung fibroma [12], suggesting more-directly-relevant activity that could be potentially beneficial as a treatment of COVID-19 patients with ARDS.Development of new generation immunol. based cytokinestorm inhibitors remains an important endeavor.Even if a successful vaccine is developed for COVID-19 patients, there will be ongoing mortality in vulnerable populations after vaccination as has been observed in flu virus and other current or future coronavirus infections as well as those with sepsis.In these conditions, resolution or chronicity of disease depends upon the strength of regulatory immune processes which appear to be compromised in COVID-19 patients that develop ARDS.To this end, the DRhQ construct could lend a helping hand.